Loeb S - Search Results

1

Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?

Loeb S, Gupta A, Losonczy L, Tosoian J, Walsh PC. Loeb S, et al. Curr Opin Urol. 2013 Jan;23(1):2-4. doi: 10.1097/MOU.0b013e32835abcf2. Curr Opin Urol. 2013. PMID: 23159990 Review.

2

Accuracy of prostate weight estimation by digital rectal examination versus transrectal ultrasonography.

Loeb S, Han M, Roehl KA, Antenor JA, Catalona WJ. Loeb S, et al. J Urol. 2005 Jan;173(1):63-5. doi: 10.1097/01.ju.0000145883.01068.5f. J Urol. 2005. PMID: 15592029

3

Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years.

Nadler RB, Loeb S, Roehl KA, Antenor JA, Eggener S, Catalona WJ. Nadler RB, et al. Among authors: loeb s. J Urol. 2005 Dec;174(6):2154-7, discussion 2157. doi: 10.1097/01.ju.0000181213.07447.8f. J Urol. 2005. PMID: 16280754

4

Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.

Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Loeb S, et al. Urology. 2006 Feb;67(2):316-20. doi: 10.1016/j.urology.2005.08.040. Epub 2006 Jan 25. Urology. 2006. PMID: 16442597

5

Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JA, Yap RL, Catalona WJ. Loeb S, et al. J Urol. 2006 Mar;175(3 Pt 1):902-6. doi: 10.1016/S0022-5347(05)00327-7. J Urol. 2006. PMID: 16469576

6

Viewpoint: expanding prostate cancer screening.

Catalona WJ, Loeb S, Han M. Catalona WJ, et al. Among authors: loeb s. Ann Intern Med. 2006 Mar 21;144(6):441-3. doi: 10.7326/0003-4819-144-6-200603210-00012. Ann Intern Med. 2006. PMID: 16549857

7

Management of the complications of external beam radiotherapy and brachytherapy.

Loeb S, Nadler RB. Loeb S, et al. Curr Urol Rep. 2006 May;7(3):200-8. doi: 10.1007/s11934-006-0022-0. Curr Urol Rep. 2006. PMID: 16630523 Review.

8

Lymphovascular invasion in radical prostatectomy specimens: prediction of adverse pathologic features and biochemical progression.

Loeb S, Roehl KA, Yu X, Antenor JA, Han M, Gashti SN, Yang XJ, Catalona WJ. Loeb S, et al. Urology. 2006 Jul;68(1):99-103. doi: 10.1016/j.urology.2006.02.004. Epub 2006 Jun 27. Urology. 2006. PMID: 16806410

9

Comparison of methods for calculating prostate specific antigen velocity.

Yu X, Han M, Loeb S, Gashti SN, Yeh JT, Roehl KA, Catalona WJ. Yu X, et al. Among authors: loeb s. J Urol. 2006 Dec;176(6 Pt 1):2427-31; discussion 2431. doi: 10.1016/j.juro.2006.08.006. J Urol. 2006. PMID: 17085120

10

Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, Catalona WJ. Loeb S, et al. J Urol. 2007 Jan;177(1):102-6; discussion 106. doi: 10.1016/j.juro.2006.08.097. J Urol. 2007. PMID: 17162013

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results